A Phase 1/2a Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation, Including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (CMML)

Trial Profile

A Phase 1/2a Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation, Including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (CMML)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs E 6201 (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies
  • Focus Adverse reactions; Proof of concept
  • Sponsors Strategia Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.
    • 15 Sep 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top